All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MigVax-101
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Vaccine
Partner/Sponsor/Collaborator: OurCrowd
Deal Size: $100.0 Million Upfront Cash: Undisclosed
Deal Type: Funding June 02, 2020
Details:
First investments to include MigVax - Israeli contender to produce oral coronavirus vaccine, and Sight Diagnostics - rapid, accurate and safe blood test technology in use at hospitals with COVID-19 patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Anti-SARS-CoV-2 polyclonal immunoglobulin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Kedrion
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 27, 2020
Details:
Kedrion will supply plasma from convalescent COVID-19. Kamada will be responsible for development, manufacturing and distribution of the product in territories not under kedrion’s responsibility.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): COVID-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Vaccine
Partner/Sponsor/Collaborator: OurCrowd
Deal Size: $12.0 million Upfront Cash: Undisclosed
Deal Type: Financing April 22, 2020
Details:
Investment will accelerate path to clinical trials and bring Israel’s human coronavirus vaccine to market.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Opaganib,Hydroxychloroquine Sulphate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 14, 2020
Details:
Opaganib was administered in addition to standard-of-care, including hydroxychloroquine background therapy, and was well tolerated.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Antibiotics
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Undisclosed
Partner/Sponsor/Collaborator: Mediforum Pharm
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration April 10, 2020
Details:
SuperTrans is completing a candidate evaluation of COVID-19 therapy based on its transmission technology.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PLX cells
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 12, 2020
Details:
Pre-clinical findings of PLX cells revealed significant therapeutic effects in animal studies of pulmonary hypertension, lung fibrosis, acute kidney injury and gastrointestinal in COVID-19 infection.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): rVaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Vaccine
Partner/Sponsor/Collaborator: Dyadic International, Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 25, 2020
Details:
The research collaboration combines IIBR's renowned scientific capabilities and cGMP facilities with Dyadic's patented and proprietary C1 gene expression platform.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
